Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: Non-vitamin K oral anticoagulants (NOACs) are commonly used for prophylaxis of venous thromboembolism (VTE) in orthopedic patients. Despite known safety and high potency of NOACs, potential interactions of NOACs with genetic polymorphisms are poorly understood. Dabigatran etexilate is one of the most commonly prescribed direct thrombin inhibitors for the prevention of VTE. The objectives of this study were to assess the effect of (rs1045642 and rs4148738) and (rs2244613) polymorphisms on dabigatran pharmacokinetics in patients after total knee arthroplasty.
Patients And Methods: A total of 60 patients, aged 37-81 years, who underwent surgery for knee replacement have been included in the study. VTE prophylaxis was conducted via administration of dabigatran etexilate 220 mg once daily. Genotyping for carrier state of polymorphic variants such as rs1045642 and rs4148738 of the gene and rs2244613 of the gene was carried out using real-time polymerase chain reaction (PCR). We also measured the peak and trough concentrations of plasma dabigatran by using high-performance liquid chromatography (HPLC).
Results: Our study revealed that TT genotype of rs1045642 polymorphism of the gene was associated with higher dabigatran equilibrium peak concentrations and the higher risk of bleeding than the presence of CC genotype (<0.008). There was no statistically significant genotype-dependent difference in the trough concentrations between rs1045642 and rs4148738 of the gene and rs2244613 of the gene.
Conclusion: Our findings indicate that the polymorphisms of rs1045642 may have a prominent contribution to the safety of dabigatran in patients after knee surgery. Moreover, TT genotype may be associated with the higher risk of hemorrhagic complications in this population. There were no influence of polymorphism of rs4148738 and rs2244613 on dabigatran peak and through concentrations. Larger studies are needed to confirm our observations.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6064159 | PMC |
| http://dx.doi.org/10.2147/PGPM.S169277 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Effect of Gene Polymorphism on the Pharmacokinetics and Clinical Outcomes of Rivaroxaban: State-of-the-Art Review.
Drug Des Devel Ther
September 2025
School of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou, People's Republic of China.
Rivaroxaban is a direct oral anticoagulant (DOAC) that directly inhibits coagulation factor Xa and exerts its anticoagulant effects. Although rivaroxaban generally exhibits predictable pharmacokinetic (PK) and pharmacodynamic (PD) profiles, significant interindividual variability in therapeutic responses exists. Research on the role of genetic factors in the clinical variability of rivaroxaban is relatively new and extensive.
View Article and Find Full Text PDFGenetic Modulation of Silodosin Exposure and Efficacy: The Role of CYP3A4, CYP3A5, and UGT2B7 Polymorphisms in Benign Prostatic Hyperplasia Management.
J Pers Med
August 2025
Federal State Budgetary Educational Institution of Further Professional Education "Russian Medical Academy of Continuous Professional Education", Ministry of Healthcare of the Russian Federation, Barrikadnaya Str. 2/1, Bld. 1, Moscow 125993, Russia.
: Silodosin, a selective α1A-adrenoceptor antagonist, is used to treat lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH). Genetic polymorphisms in drug-metabolizing enzymes and transporters may contribute to interindividual variability in its efficacy and safety. This study aimed to investigate the influence of CYP3A4, CYP3A5, UGT2B7, and ABCB1 polymorphisms on silodosin pharmacokinetics, efficacy, and safety in Russian patients with BPH.
View Article and Find Full Text PDFPharmacogenetics of dabigatran and apixaban in association with gastrointestinal bleeding.
Neuro Endocrinol Lett
November 2024
2nd Department of Internal Medicine - Gastroenterology, University Hospital Hradec Kralove and Faculty of Medicine, Hradec Kralove, Charles University, Czech Republic.
Objectives: To determine whether selected single nucleotide polymorphisms (SNPs) of genes encoding proteins responsible for the activation, transport, or metabolism of dabigatran and apixaban might be associated with a risk of gastrointestinal bleeding in a cohort of adult patients treated with these drugs. No previous study has focused specifically on the association with gastrointestinal bleeding.
Materials And Methods: Ninety-one patients treated with dabigatran or apixaban were genotyped for selected polymorphisms.
Bleeding Events Associated with Rivaroxaban Therapy in Naive Patients with Nonvalvular Atrial Fibrillation: A Longitudinal Study from a Genetic Perspective with INR Follow-Up.
Medicina (Kaunas)
October 2024
Department of Pharmacy, Shaheed Benazir Bhutto University Sheringal, Dir Upper 18000, Khyber Pakhtunkhwa, Pakistan.
: Rivaroxaban is a direct-acting anticoagulant used to prevent stroke in patients with atrial fibrillation. Rivaroxaban is a substrate for P-glycoprotein, which is encoded by the ABCB1 gene. Rivaroxaban is also metabolized by the CYP3A5 gene.
View Article and Find Full Text PDFGenetic variants of and genes on dabigatran metabolism in the Kazakh population.
Caspian J Intern Med
January 2024
Department of Arrhythmology, National Research Cardiac Surgery Center, Turan 38, Astana, Kazakhstan.
Article Synopsis
- The study investigates how genetic variations in certain genes affect the metabolism and effects of the blood thinner dabigatran in patients with atrial fibrillation.
- Using TaqMan technology, the research analyzed genotypes from 150 patients and found significant differences in dabigatran concentrations based on specific gene polymorphisms.
- The findings suggest that polymorphisms rs8192935 and rs2244613 influence dabigatran's pharmacodynamics and pharmacokinetics, particularly in the Kazakh population.